192 related articles for article (PubMed ID: 35690832)
1. The immune landscape of solid pediatric tumors.
Sherif S; Roelands J; Mifsud W; Ahmed EI; Raynaud CM; Rinchai D; Sathappan A; Maaz A; Saleh A; Ozer E; Fakhro KA; Mifsud B; Thorsson V; Bedognetti D; Hendrickx WRL
J Exp Clin Cancer Res; 2022 Jun; 41(1):199. PubMed ID: 35690832
[TBL] [Abstract][Full Text] [Related]
2. Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma.
Yu Y; Zeng Y; Xia X; Zhou JG; Cao F
Cancer Control; 2021; 28():10732748211033751. PubMed ID: 34569303
[TBL] [Abstract][Full Text] [Related]
3. Exploration of the molecular characteristics of the tumor-immune interaction and the development of an individualized immune prognostic signature for neuroblastoma.
Jin W; Zhang Y; Liu Z; Che Z; Gao M; Peng H
J Cell Physiol; 2021 Jan; 236(1):294-308. PubMed ID: 32510620
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
Yang H; Zhao L; Zhang Y; Li FF
Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
[TBL] [Abstract][Full Text] [Related]
5. Disparity in Outcomes for Adolescent and Young Adult Patients Diagnosed With Pediatric Solid Tumors Across 4 Decades.
Chen I; Pasalic D; Fischer-Valuck B; Frangoul H; DeWees T; Shinohara ET; Perkins SM
Am J Clin Oncol; 2018 May; 41(5):471-475. PubMed ID: 27841802
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.
Hu C; Liu C; Tian S; Wang Y; Shen R; Rao H; Li J; Yang X; Chen B; Ye L
BMC Cancer; 2020 Aug; 20(1):814. PubMed ID: 32854645
[TBL] [Abstract][Full Text] [Related]
7. Immune contexture of paediatric cancers.
Thakur MD; Franz CJ; Brennan L; Brouwer-Visser J; Tam R; Korski K; Koeppen H; Ziai J; Babitzki G; Ranchere-Vince D; Vasiljevic A; Dijoud F; Marec-Bérard P; Rochet I; Cannarile MA; Marabelle A
Eur J Cancer; 2022 Jul; 170():179-193. PubMed ID: 35660252
[TBL] [Abstract][Full Text] [Related]
8. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
Higgs EF; Bao R; Hatogai K; Gajewski TF
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705315
[TBL] [Abstract][Full Text] [Related]
9. Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis.
Marchais A; Marques da Costa ME; Job B; Abbas R; Drubay D; Piperno-Neumann S; Fromigué O; Gomez-Brouchet A; Redini F; Droit R; Lervat C; Entz-Werle N; Pacquement H; Devoldere C; Cupissol D; Bodet D; Gandemer V; Berger M; Marec-Berard P; Jimenez M; Vassal G; Geoerger B; Brugières L; Gaspar N
Cancer Res; 2022 Mar; 82(6):974-985. PubMed ID: 35078815
[TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
11. Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
Valind A; Gisselsson D
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1397. PubMed ID: 33932141
[TBL] [Abstract][Full Text] [Related]
12. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.
Liu R; Hu Y; Liu T; Wang Y
BMC Cancer; 2021 Dec; 21(1):1345. PubMed ID: 34922489
[TBL] [Abstract][Full Text] [Related]
13. Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes.
Song YJ; Xu Y; Deng C; Zhu X; Fu J; Chen H; Lu J; Xu H; Song G; Tang Q; Wang J
Front Immunol; 2021; 12():623762. PubMed ID: 33959121
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures.
Tan J; Feng X; Wu H; Yang B; Shi M; Xie C; Su Z; Li L; Luo M; Zuo Z; Zhu S; Yang J; Lin L
J Immunol Res; 2022; 2022():6568278. PubMed ID: 36065454
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of apoptosis-related signature and molecular subtype to improve prognosis prediction in osteosarcoma patients.
Hong J; Li Q; Wang X; Li J; Ding W; Hu H; He L
J Clin Lab Anal; 2022 Jul; 36(7):e24501. PubMed ID: 35576501
[TBL] [Abstract][Full Text] [Related]
16. Identification of two immune subtypes in osteosarcoma based on immune gene sets.
Yang M; Cao Y; Wang Z; Zhang T; Hua Y; Cai Z
Int Immunopharmacol; 2021 Jul; 96():107799. PubMed ID: 34162161
[TBL] [Abstract][Full Text] [Related]
17. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
18. Immunological landscape of Neuroblastoma and its clinical significance.
Batchu S
Cancer Treat Res Commun; 2021; 26():100274. PubMed ID: 33338852
[TBL] [Abstract][Full Text] [Related]
19. Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma.
Hu B; Wei Q; Zhou C; Ju M; Wang L; Chen L; Li Z; Wei M; He M; Zhao L
Int Immunopharmacol; 2020 Dec; 89(Pt A):107162. PubMed ID: 33168410
[TBL] [Abstract][Full Text] [Related]
20. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
Bao R; Spranger S; Hernandez K; Zha Y; Pytel P; Luke JJ; Gajewski TF; Volchenboum SL; Cohn SL; Desai AV
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
